Search

Haywayrd-based biopharmaceutical firm MicuRx said this morning that it has raised $25M in a Series B funding. The company, which is developing antibiotics, said the funding was led by BVCF, and also included Morningside Group and Devon Park Bioventures. MicuRx said the funding will go to support development of an antibiotic targeting infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Weixin Xu and Davis Yang of BVCF have both joined the company's board as part of the investment.
posted on Thursday, August 22, 2013 (Link to more information)

Related companies:
MicuRx

Related stories:
> MicuRx Pharmaceuticals Gets $55M For Antibiotics Development
> MicuRx Raises $10M
> Xamarin Finds $16M For App Development Tools
> U-Systems Finds $16.5M
> Metamarkets Finds $15M For Big Data Analytics

---

silicontap.com Home